Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

20.18 +0.99 (+5.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop
Via Investor Brand Network
Exposures COVID-19 Product Safety
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances 
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's Going On With Tonix Pharmaceuticals Stock Friday?
Tonix shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) Receives New US Patent for Subcutaneous Administration of Zembrace(R) SymTouch(R) to Treat Migraines
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Looking Into Tonix Pharmaceuticals's Recent Short Interest
Via Benzinga
As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
Via ACCESSWIRE
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Participate in Global Conference with Three TNX-102 SL Data Presentations
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox
Via Investor Brand Network
Exposures Product Safety
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Names Seasoned Veteran as New EVP of Commercial Operations
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox
Via Investor Brand Network
Exposures Product Safety
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Tonix Pharmaceuticals shares jumped 38% after presenting data on TNX-801, a potential single-dose mpox vaccine. Preclinical studies suggest it could block transmission and offer improved protection. 
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Educational Campaign to Inspire Patients to Optimize Migraine Treatment Plans with Non-Oral Medication
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia
Via Investor Brand Network
Exposures Product Safety
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
Tonix Pharmaceuticals and Bilthoven Biologicals have partnered to advance TNX-801, a promising mpox vaccine candidate based on horsepox. Backed by the world's largest vaccine manufacturer, the... 
Via Benzinga
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years Worldwide availability and... 
Via FinancialNewsMedia
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
Via ACCESSWIRE
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Tonix Pharmaceuticals shares are traded lower on Tuesday. The stock is pulling back after a 60% gain on Monday following the company's Q2 earnings report. 
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
TNXP stock results show that Tonix Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
Tonix Pharmaceuticals advances TNX-801, a live attenuated horsepox virus vaccine for mpox and infectious diseases, with promising preclinical results. WHO declares mpox a global health emergency amid... 
Via Benzinga
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
Via ACCESSWIRE
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
Via ACCESSWIRE
Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya™ for fibromyalgia management
Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya™ for fibromyalgia management 
Via News Direct
Exposures Product Safety
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.